|
|
Expanzi aktivovaných CD8+ t-lymfocytů lze výrazně zvýšit podáváním komplexů IL-2 a anit-IL-2protilátky
Tomala, Jakub ; Kovář, Marek ; Strohalm, Jiří ; Etrych, Tomáš ; Ulbrich, Karel ; Říhová, Blanka
By using the model of adoptively transferred transgenic CD8+ cells (OT-I) labeled by CFSE dye, we have measured clonal expansion, proliferation and expression of surface markers after various stimulation.We have studies prophylactic effect of complexes, alone or in combination with other cytokines, on various cancer cell lines in vivo. Our results indicate such approach is very promising and could be potent therapeutical tool in tratment of cancer
|
|
|
Polymerní konjugát doxorubicinu na bázi HPMA, působící ve shodě s protinádorovou imunitou nositele
Šírová, Milada ; Rossmann, Pavel ; Mrkvan, Tomáš ; Strohalm, Jiří ; Šubr, Vladimír ; Plocová, Daniela ; Ulbrich, Karel ; Říhová, Blanka
Polymeric conjugate Dox-HPMA-HuIg directly targets the tumour due to the EPR effect, it is not detrimental towards the immune system of the host, and acts in concert with the anti-tumour immune responses
|
|
|
Glykosylace povrchové membrány EL-4 buněk: vliv volného nebo N-(2-hydroxypropyl)methacrylamide (HPMA) vázaného doxorubicinu
Kovář, Lubomír ; Etrych, Tomáš ; Šubr, Vladimír ; Strohalm, Jiří ; Sklenář, Jan ; Chytil, Petr ; Ulbrich, Karel ; Říhová, Blanka
In those experimenst we studied the possible impace of CD43 as highly glycosylated molecule in cells exposed to free doxorubicin (Dox) or to conjugates consisting of HPMA copolymer backbone to which the drug is conjugated via enzymatically (PK1 conjugate) or pH sensitive, hydrolytically cleavable bond (hydrazone conjugate, HYD).
|
|
|
Imunostimulační a imunoprotektivní vlastnosti makromolekulárních protinádorových léčiv
Říhová, Blanka ; Strohalm, Jiří ; Šírová, Milada ; Etrych, Tomáš ; Mrkvan, Tomáš ; Šubr, Vladimír ; Plocová, Daniela ; Kovář, Marek ; Ulbrich, Karel
Polymeric conjugates of doxorubicin, non-targeted or antibody targeted cure mice from experimental EL4 T cell lymphoma and induce specific, systemic long-lasting anti/tumor resistance
|
|
| |
|
| |
|
|
Kopolymery na bázi HPMA s pH-řízeným uvolňováním doxorubicinu v protinádorové terapii umožňují imunitnímu systému rozpoznat nádor
Mrkvan, Tomáš ; Šírová, Milada ; Etrych, Tomáš ; Chytil, Petr ; Strohalm, Jiří ; Plocová, Daniela ; Ulbrich, Karel ; Říhová, Blanka
Therapy with HPMA-based conjugates triggers effective anti-tumour immunity early during the course of the treatment. Activated immune system, in addition to direct cytotoxic effect the drug, is responsible for the eradication of established tumour
|
|
|
Voltammetric Determination of Cytostatic Using Silver Solid Amalgam Electrode
Barek, J. ; Fischer, J. ; Konečná, B. ; Kratzer, J. ; Hrušková, M. ; Navrátil, Tomáš ; Novotný, Ladislav ; Josypčuk, Bohdan ; Zima, J.
Modern polarographic and voltammetric methods at mercury meniscus-modified silver solid amalgam electrode (m-AgSAE) were proved to be suitable for the determination of a number of polarographically active cytostatic drugs. The voltammetric determination of 6-mercaptupurine (6-MP), 6-thioguanine (6-TG), Mitoxantrone (MX, CAS No.: 65271-80-9, CAS. Name: 1,4-Dihydroxy-5,8-bis[{2-[(2-hydroxyethyl)amino]ethyl}amino]-9,10-anthracenedione), and Doxorubicin (DR, CAS No.: 23214-92-8, CAS Name: (8S-cis)-10-[(3-Amino-2,3,6-trideoxy--L-lyxohexapyranosyl)oxy] - 7, 8, 9, 10 - tetrahydro-6, 8, 11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphtacenedione) were studied.
|
|
|
Activity of doxorubicin bound to polymeric carrier, containing human IgG was followed in four patients with breast carcinoma
Pokorná, Jindřiška ; Strohalm, Jiří ; Kubáčková, K. ; Jelínková, Markéta ; Rozprimová, L. ; Šírová, Milada ; Plocová, Daniela ; Etrych, Tomáš ; Ulbrich, Karel ; Říhová, Blanka
More than 116 biochemical and immunological parameters wasfollowed in patients with carcinoma.
|
|
| |
guest ::
